XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB)

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the resea…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

4

Website

www.xtlbio.com/

Fundamentals

1-day range

$2.54$2.58

Market cap

$7.03M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

—

Dividend yield

—

Beta

0.76

Avg. volume

71.4K

Dividend pay date

February 10, 2017

XTL Biopharmaceuticals Ltd. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• XTLB

  XTL Biopharmaceuticals Ltd. American Depositary Shares

  $2.47

  ▼ 4.26%
  Market cap $7.03MP/E —
  $1.6$11.8
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.09MP/E —
  $1.67$14.24
• TRAW

  Traws Pharma Inc. Common Stock

  $0.59

  ▲ 0.00%
  Market cap $7.18MP/E —
  $0.4301$3.27
• APUS

  Apimeds Pharmaceuticals US Inc. Common Stock

  $3.87

  ▼ 1.28%
  Market cap $7.32MP/E —
  $3.39$403.1
• APRE

  Aprea Therapeutics Inc. Common stock

  $0.8387

  ▼ 2.48%
  Market cap $7.40MP/E —
  $0.548$1.69
• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.42MP/E —
  $0.84$2.68
• MTVA

  MetaVia Inc. Common Stock

  $1.71

  ▲ 3.01%
  Market cap $7.64MP/E —
  $0.9661$19.03

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

72.7K

Total value held

$55.5K

Institutional holders

6